

# Calvin Yeang

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5233022/publications.pdf>

Version: 2024-02-01

45  
papers

2,903  
citations

236925

25  
h-index

243625

44  
g-index

46  
all docs

46  
docs citations

46  
times ranked

3113  
citing authors

#	ARTICLE	IF	CITATIONS
1	Clonal hematopoiesis driven by DNMT3A and TET2 mutations: role in monocyte and macrophage biology and atherosclerotic cardiovascular disease. <i>Current Opinion in Hematology</i> , 2022, 29, 1-7.	2.5	29
2	Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement From the American Heart Association. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2022, 42, ATV000000000000147.	2.4	207
3	Trends in testing and prevalence of elevated Lp(a) among patients with aortic valve stenosis. <i>Atherosclerosis</i> , 2022, 349, 144-150.	0.8	9
4	Effect of Pelacarsen on Lipoprotein(a) Cholesterol and Corrected Low-Density Lipoprotein Cholesterol. <i>Journal of the American College of Cardiology</i> , 2022, 79, 1035-1046.	2.8	65
5	Novel method for quantification of lipoprotein(a)-cholesterol: implications for improving accuracy of LDL-C measurements. <i>Journal of Lipid Research</i> , 2021, 62, 100053.	4.2	62
6	Abstract 11456: Elevated Lipoprotein(a) is Associated with Statin Resistance. <i>Circulation</i> , 2021, 144, .	1.6	0
7	Statins and increases in Lp(a): an inconvenient truth that needs attention. <i>European Heart Journal</i> , 2020, 41, 192-193.	2.2	20
8	Statin therapy increases lipoprotein(a) levels. <i>European Heart Journal</i> , 2020, 41, 2275-2284.	2.2	265
9	Generation and characterization of LPA-KIV9, a murine monoclonal antibody binding a single site on apolipoprotein (a). <i>Journal of Lipid Research</i> , 2020, 61, 1263-1270.	4.2	8
10	Low-Density Lipoprotein Cholesterol Corrected for Lipoprotein(a) Cholesterol, Risk Thresholds, and Cardiovascular Events. <i>Journal of the American Heart Association</i> , 2020, 9, e016318.	3.7	26
11	Short-term regulation of hematopoiesis by lipoprotein(a) results in the production of pro-inflammatory monocytes. <i>International Journal of Cardiology</i> , 2020, 315, 81-85.	1.7	13
12	Atherogenic Lipoprotein(a) Increases Vascular Glycolysis, Thereby Facilitating Inflammation and Leukocyte Extravasation. <i>Circulation Research</i> , 2020, 126, 1346-1359.	4.5	96
13	ApoCIII-Lp(a) complexes in conjunction with Lp(a)-OxPL predict rapid progression of aortic stenosis. <i>Heart</i> , 2020, 106, 738-745.	2.9	28
14	Ancient Remedy for a Modern Disease. <i>JACC Basic To Translational Science</i> , 2020, 5, 50-52.	4.1	2
15	The interconnection between lipoprotein(a), lipoprotein(a) cholesterol and true LDL-cholesterol in the diagnosis of familial hypercholesterolemia. <i>Current Opinion in Lipidology</i> , 2020, 31, 305-312.	2.7	11
16	Reduction of myocardial ischaemia-reperfusion injury by inactivating oxidized phospholipids. <i>Cardiovascular Research</i> , 2019, 115, 179-189.	3.8	61
17	Potent reduction of plasma lipoprotein (a) with an antisense oligonucleotide in human subjects does not affect ex vivo fibrinolysis. <i>Journal of Lipid Research</i> , 2019, 60, 2082-2089.	4.2	35
18	Lipoprotein(a) in Patients Undergoing Transcatheter Aortic Valve Replacement. <i>Angiology</i> , 2019, 70, 332-336.	1.8	6

#	ARTICLE	IF	CITATIONS
19	Relationship between $\Delta$ LDL-C, estimated true LDL-C, apolipoprotein B-100, and PCSK9 levels following lipoprotein(a) lowering with an antisense oligonucleotide. <i>Journal of Clinical Lipidology</i> , 2018, 12, 702-710.	1.5	53
20	PET/MR Imaging of Malondialdehyde-Acetaldehyde Epitopes With a Human Antibody Detects Clinically Relevant Atherothrombosis. <i>Journal of the American College of Cardiology</i> , 2018, 71, 321-335.	2.8	39
21	Association of Mild to Moderate Aortic Valve Stenosis Progression With Higher Lipoprotein(a) and Oxidized Phospholipid Levels. <i>JAMA Cardiology</i> , 2018, 3, 1212.	6.1	76
22	Oxidized phospholipids are proinflammatory and proatherogenic in hypercholesterolaemic mice. <i>Nature</i> , 2018, 558, 301-306.	27.8	359
23	The Prevalence of Lipoprotein(a) Measurement and Degree of Elevation Among 2710 Patients With Calcific Aortic Valve Stenosis in an Academic Echocardiography Laboratory Setting. <i>Angiology</i> , 2017, 68, 795-798.	1.8	10
24	Novel Lipoprotein(a) Catabolism Pathway via Apolipoprotein(a) Recycling. <i>Circulation Research</i> , 2017, 120, 1050-1052.	4.5	14
25	Lipoprotein(a)-Associated Molecules Are Prominent Components in Plasma and Valve Leaflets in Calcific Aortic Valve Stenosis. <i>JACC Basic To Translational Science</i> , 2017, 2, 229-240.	4.1	61
26	Lipoprotein(a) and oxidized phospholipids in calcific aortic valve stenosis. <i>Current Opinion in Cardiology</i> , 2016, 31, 440-450.	1.8	55
27	Effect of therapeutic interventions on oxidized phospholipids on apolipoprotein B100 and lipoprotein(a). <i>Journal of Clinical Lipidology</i> , 2016, 10, 594-603.	1.5	88
28	PCSK9 Association With Lipoprotein(a). <i>Circulation Research</i> , 2016, 119, 29-35.	4.5	99
29	The role of lipoprotein(a) in progression of renal disease: Causality or reverse causality?. <i>Journal of Diabetes and Its Complications</i> , 2016, 30, 755-757.	2.3	1
30	Lipoprotein(a)-cholesterol levels estimated by vertical auto profile correlate poorly with Lp(a) mass in hyperlipidemic subjects: Implications for clinical practice interpretation of Lp(a)-mediated risk. <i>Journal of Clinical Lipidology</i> , 2016, 10, 1389-1396.	1.5	20
31	Oxidized Phospholipids on Lipoprotein(a) Elicit Arterial Wall Inflammation and an Inflammatory Monocyte Response in Humans. <i>Circulation</i> , 2016, 134, 611-624.	1.6	396
32	Experimental Animal Models Evaluating the Causal Role of Lipoprotein(a) in Atherosclerosis and Aortic Stenosis. <i>Cardiovascular Drugs and Therapy</i> , 2016, 30, 75-85.	2.6	31
33	$\Delta$ LDL-C $\approx$ $\Delta$ LDL-C + $\Delta$ Lp(a)-C. <i>Current Opinion in Lipidology</i> , 2015, 26, 169-178.	2.7	122
34	HDL-C, ABCA1-mediated cholesterol efflux, and lipoprotein(a): insights into a potential novel physiologic role of lipoprotein(a). <i>Journal of Lipid Research</i> , 2015, 56, 1241-1244.	4.2	2
35	Oxidized Phospholipids, Lipoprotein(a), and Progression of Calcific Aortic Valve Stenosis. <i>Journal of the American College of Cardiology</i> , 2015, 66, 1236-1246.	2.8	295
36	Abstract 14697: Novel Assays for Quantification of Lipoprotein-Associated (PCSK9-apoB, PCSK9-Lp(a)) Proprotein Convertase Subtilisin/Kexin Type 9 (PCKS9). <i>Circulation</i> , 2015, 132, .	1.6	2

#	ARTICLE	IF	CITATIONS
37	Molecular Imaging of Oxidation-Specific Epitopes to Detect High-Risk Atherosclerotic Plaques. , 2015, , 121-154.		0
38	Imaging of Oxidation-Specific Epitopes with Targeted Nanoparticles to Detect High-Risk Atherosclerotic Lesions: Progress and Future Directions. Journal of Cardiovascular Translational Research, 2014, 7, 719-736.	2.4	18
39	Sphingomyelin synthase 2 (SMS2) deficiency attenuates LPS-induced lung injury. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2011, 300, L430-L440.	2.9	42
40	Role of Phospholipid Transfer Protein in High-Density Lipoprotein-Mediated Reverse Cholesterol Transport. Current Atherosclerosis Reports, 2011, 13, 242-248.	4.8	42
41	Subcellular Targeting Domains of Sphingomyelin Synthase 1 and 2. Nutrition and Metabolism, 2011, 8, 89.	3.0	23
42	Diet-induced lipid accumulation in phospholipid transfer protein-deficient mice: its atherogenicity and potential mechanism. Journal of Lipid Research, 2010, 51, 2993-3002.	4.2	4
43	Sphingomyelin biosynthesis: its impact on lipid metabolism and atherosclerosis. Clinical Lipidology, 2009, 4, 595-609.	0.4	8
44	The domain responsible for sphingomyelin synthase (SMS) activity. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2008, 1781, 610-617.	2.4	53
45	Phospholipid Transfer Protein-Deficient Mice Absorb Less Cholesterol. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, 2014-2021.	2.4	39